Granted Patent B2

US 10,993,984 · App. 16/343,232 · Granted May 4, 2021

Abstract

Claims (13)

1. A method of treating a subject suffering from ascites, the method comprising orally administering to the subject a pharmaceutical composition configured as a tablet or capsule, wherein the pharmaceutical composition comprises a therapeutically effective amount of terlipressin or a pharmaceutically acceptable salt thereof, thereby treating the subject.

2. The method of claim 1 , wherein the tablet or capsule is administered 1, 2, 3 or 4 times daily.

3. The method of claim 1 , wherein the tablet or capsule comprises 5 to 30 mg terlipressin or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the subject is administered 5 to 100 mg terlipressin daily.

5. The method of claim 1 , wherein the terlipressin is administered for about one day to about 12 months.

6. The method of claim 1 , wherein the terlipressin dose escalates over about one day to about 12 months.

7. The method of claim 1 , wherein the method results in reduced side effects relative to a method of administering terlipressin by other forms of administration.

8. The method of claim 1 , wherein the ascites is associated with liver cirrhosis.

9. The method of claim 8 , wherein the terlipressin is administered in combination with a diuretic, albumin, a beta blocker, or a vasopressin V2-receptor antagonist (vaptan).

10. The method of claim 4 , wherein the subject is administered 20 to 100 mg terlipressin daily.

11. The method of claim 10 , wherein the subject is administered 40 to 100 mg terlipressin daily.

12. The method of claim 10 , wherein the subject is administered 60 to 100 mg terlipressin daily.

13. The method of claim 10 , wherein the subject is administered 80 mg terlipressin daily.

Assignments (6)